Product nameRecombinant Hepatitis C Virus Core 2b protein
Protein lengthProtein fragment
Amino Acid Sequence
Amino acids2 to 119
Our Abpromise guarantee covers the use of ab91302 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Biological activityab91302 is immunoreactive with sera of HCV-infected individuals.
Purity> 95 % SDS-PAGE.
ab91302 is purified by proprietary chromatographic techniques. Purity is >95% by SDS-PAGE and RP-HPLC.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Constituents: 0.79% Tris HCl, 0.146% EDTA
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- HCV 2b
- HCV Core 2b
- HCV Core Genotype 2b
RelevanceHCV (Hepatitis C Virus) viral core protein forms the internal viral coat that encapsidates the genomic RNA and is enveloped in a host cell-derived lipid membrane. The hepatitis C virus (HCV) core protein represents the first 177 amino acids of the viral precursor polyprotein and is cotranslationally inserted into the membrane of the endoplasmic reticulum. The N terminus of the core protein is involved in transcriptional repression. There are over 20 different subtypes of Hepatitis C Virus. The preponderance and distribution of HCV genotypes varies globally. HCV Genotype information is important because of the role it plays in predicting HCV medical treatment response and treatment duration. Sustained cure rates (sustained viral response) of 75% or better occur in people with genotypes HCV 2 and 3 in 24 weeks of treatment. Genotypes 1a and 1b, the most prevalent worldwide, have the poorest rates of response to the present treatment regimen, which is a combination of pegylated alfa interferon 2b with ribavirin. HCV core protein is among the most conserved proteins in HCV and is known to induce sensitization of cytotoxic T lymphocytes (CTL). Therefore, it is a prime candidate for a component of a potential HCV vaccine.
ab91302 has not yet been referenced specifically in any publications.